AACR releases 2017 cancer progress report

September 14, 2017

(HealthDay)—The age-adjusted U.S. cancer death rate decreased 25 percent from 1991 to 2014, which translates into 2.1 million fewer cancer deaths, according to an annual progress report published by the American Association for Cancer Research.

The AACR Cancer Progress Report 2017 provides an overview of the progress being made because of research, as well as the need for continued research innovation.

According to the report, a rapid pace of research in the field of immunology has facilitated development of lifesaving immunotherapeutics. As of July 2017, immunotherapeutics were approved for treating seven different types of cancer and for treatment of solid tumors characterized by the presence of a specific molecular signature or biomarker. New and expanded uses for immunotherapeutics include for Lynch syndrome, Merkel cell carcinoma, and head and neck cancer. From Aug. 1, 2016, to July 31, 2017, the U.S. Food and Drug Administration approved nine new anticancer therapeutics, a new optical imaging agent to help visualize cancerous tissue during surgery, and new uses for eight previously approved therapeutics. New therapeutics targeting specific molecules involved in the cancer process include a PARP inhibitor for ovarian cancer, a PDGFR-alpha-targeted therapeutic for , and the first FLT3 inhibitor for .

"As research has taught us more about the biology of cancer, we have made incredible advances in cancer treatment and prevention that are saving lives today," Michael A. Caligiuri, M.D., president of the AACR, said in a statement.

Explore further: Drug combination boost PARP inhibitor response in resistant ovarian cancer

More information: AACR Cancer Progress Report 2017

Related Stories

Drug combination boost PARP inhibitor response in resistant ovarian cancer

April 3, 2017
About one-third of patients with ovarian cancer who wouldn't be expected to respond to a PARP inhibitor had partial shrinkage of their tumor when a kinase inhibitor was added to treatment, report scientists from Dana-Farber ...

More cancer patients gaining from immune-based treatments

September 20, 2016
(HealthDay)—A leading cancer group says more Americans are benefiting from immunotherapy—a relatively new treatment approach that helps the immune system target and destroy cancer cells.

Americans support more funding of cancer research

September 16, 2015
(HealthDay)—Major advances have been made in the fight against cancer, but Americans aren't satisfied, a new survey suggests.

Some head and neck cancer patients benefit from continued checkpoint inhibitor treatment

April 3, 2017
New research suggests that some patients with head and neck cancers can benefit by continuing treatment with an immunotherapy drug after their tumors show signs of enlargement according to investigators at Dana-Farber Cancer ...

Brain cancer now leading childhood cancer killer

September 16, 2016
Brain cancer is now the deadliest childhood cancer in the U.S., now ahead of leukemia, a result of improved leukemia treatment and a frustrating lack of progress on brain cancer.

Promising cancer treatment targets rare genetic flaw

June 4, 2017
An experimental cancer medicine called larotrectinib has shown promise treating a diverse range of cancers in people young and old, researchers said at a major cancer conference in the United States.

Recommended for you

Brain powered: Increased physical activity among breast cancer survivors boosts cognition

September 19, 2017
It is estimated that up to 75 percent of breast cancer survivors experience problems with cognitive difficulties following treatments, perhaps lasting years. Currently, few science-based options are available to help. In ...

Targeted antibiotic use may help cure chronic myeloid leukaemia

September 19, 2017
The antibiotic tigecycline, when used in combination with current treatment, may hold the key to eradicating chronic myeloid leukaemia (CML) cells, according to new research.

Researchers compose guidelines for handling CAR T cell side effects

September 19, 2017
Immune-cell based therapies opening a new frontier for cancer treatment carry unique, potentially lethal side effects that provide a new challenge for oncologists, one addressed by a team led by clinicians at The University ...

Bone marrow protein a 'magnet' for passing prostate cancer cells

September 19, 2017
Scientists at the University of York have shown that a protein in the bone marrow acts like a 'magnetic docking station' for prostate cancer cells, helping them grow and spread outside of the prostate.

Brain cancer breakthrough could provide better treatment

September 19, 2017
A new discovery about the most common type of childhood brain cancer could transform treatment for young patients by enabling doctors to give the most effective therapies.

A new paradigm for treating transcription factor-driven cancers

September 18, 2017
In the current issue of Proceedings of the National Academy of Sciences, researchers from Nationwide Children's Hospital describe a new paradigm for treating transcription factor-driven cancers. The study focuses on Ewing ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.